EVALUATION OF VASOACTIVE DRUGS WITH CLEARANCE OF RADIOSODIUM
- Can we Develop Neurally Acting Drugs for the Treatment of Migraine? Goadsby, Peter J. // Nature Reviews Drug Discovery;Sep2005, Vol. 4 Issue 9, p741
Serotonin (5-HT)1B/1D receptor agonists, which are also known as triptans, represent the most important advance in migraine therapeutics in the four millennia that the condition has been recognized. The vasoconstrictive activity of triptans produced a small clinical penalty in terms of coronary...
- Enhanced vascular responses to noradrenaline in isolated omental arteries from patients with advanced cirrhosis: evidence against intrinsic vascular hyporeactivity in cirrhosis. Vaughan, R. B.; Angus, P. W.; Angus, J. A. // Gut;Oct2004, Vol. 53 Issue 10, p1544
This article reports that the mesenteric and systemic vasodilatation that occurs in advanced liver disease leads to the development of a hyperdynamic circulatory state, which in turn underlies many of the complications of cirrhosis. Studies of isolated vessel preparations from cirrhotic animal...
- Regulation of sympathetic nerve traffic to skeletal muscle in resting humans. Wallin, B. // Clinical Autonomic Research;Aug2006, Vol. 16 Issue 4, p262
An overview is given of microneurographic studies of resting vasoconstrictor traffic in human muscle nerves (muscle sympathetic nerve activity = MSNA). In multiunit recordings, the activity consists of synchronized bursts of vasoconstrictor impulses, the outflow of which is under potent arterial...
- Comparison of the cerebral effects of dopamine and norepinephrine in severely head-injured patients. Ract, C.; Vigué, B. // Intensive Care Medicine;Jan2001, Vol. 27 Issue 1, p101
Objective: To compare the cerebral effects of dopamine and norepinephrine after severe head injury. Design: Prospective, clinical study. Setting: Surgical intensive care unit in a university hospital. Patients: Nineteen patients with severe head-injuries already requiring vasopressor therapy....
- FDA Drug Approvals: Crestor. // Formulary;Sep2003, Vol. 38 Issue 9, p509
Offers information on the pharmacology of the resuvastatin drug Crestor. Approval for treatment of lipid disorders; Performance of the drug in the treatment of patients with hypercholesterolemia; Contraindication of resuvastatin in liver disease or persistent elevations of serum transaminases.
- Beat-to-Beat Measurement of Cardiovascular Effects of a Single Subcutaneous Dose of Terbutaline in Healthy Subjects. Mulder, W.M.C.; de Klerk, S.; Settels, J.J.; van Boxtel, C.J. // Clinical Drug Investigation;2002, Vol. 22 Issue 9, p593
Objective: To evaluate the cardiovascular effects over time of a single subcutaneous (SC) dose of terbutaline 0.75mg in young healthy volunteers using continuous, beat-to-beat monitoring of cardiovascular effects. Design and methods: Nine healthy young volunteers were administered a SC dose of...
- Statin Use in Patients with Abnormal Liver Function. // Internal Medicine Alert;1/15/2011 Clinical Briefs, p1
The article offers pharmacology updates focusing on a recent study which shows that statins can improve liver abnormalities in patients with fatty liver.
- Why a New Journal in Cardiovascular Pharmacology and Therapeutics? Singh, Bramah N. // Journal of Cardiovascular Pharmacology & Therapeutics;Mar1996, Vol. 1 Issue 1, p1
The article offers information on the "Journal of Cardiovascular Pharmacology and Therapeutics."
- Mast Cell Inhibition Attenuates Myocardial Damage, Adverse Remodeling, and Dysfunction During Fulminant Myocarditis in the Rat. Mina, Yair; Rinkevich-Shop, Shunit; Konen, Eli; Goitein, Orly; Kushnir, Tammar; Epstein, Frederick H.; Feinberg, Micha S.; Leor, Jonathan; Landa-Rouben, Natalie // Journal of Cardiovascular Pharmacology & Therapeutics;Mar2013, Vol. 18 Issue 2, p152
Background: Myocarditis is a life-threatening heart disease characterized by myocardial inflammation, necrosis, and chronic fibrosis. While mast cell inhibition has been suggested to prevent fibrosis in rat myocarditis, little is known about its effectiveness in attenuating cardiac remodeling...